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Objective(s): Human	and	animal	studies	have	shown	a	close	relationship	between	obesity	and	asthma	
severity.	Here,	we	examined	the	effects	of	diet‐induced	obesity	(DIO)	on	the	expression	levels	of	IL‐1β,	
IRAK‐1	and	TRAF‐6	mRNA	in	male	Wistar	rats	tracheal	after	sensitization	with	ovalbumin	(OVA).		
Materials and Methods:	Twenty	male	Wistar	rats	divided	to	four	groups,	included,	control	group	with	
normal	diet	(C+ND),	OVA‐sensitized	group	with	normal	diet	(S+ND),	control	group	with	high‐fat	diet	
(C+HFD),	 and	 OVA‐sensitized	 group	 with	 high‐fat	 diet	 (S+HFD).	 All	 animals	 fed	 for	 8	 weeks	 with	
standard	pelts	or	high‐fat	diet,	and	then	were	sensitized	and	challenged	with	OVA	or	saline	for	another	
4	weeks	with	designed	 regimens.	At	 the	end	 of	 study,	 trachea	 isolated	 and	examined	 for	 expression	
levels	of	IL‐1β,	IRAK‐1	and	TRAF‐6	mRNA	with	RT‐PCR	method.		
Results:	Diet‐induced	 obesity	 groups	 developed	 increased	 weight,	 obesity	 indexes	 and	 lipid	 profiles	
(P<0.05	 to	 P<0.001).	 The	 expression	 levels	 of	 IL‐1β	 mRNA	 in	 OVA‐sensitization	 groups	 (S+ND	 and	
S+HFD)	 showed	 a	 significantly	 increased	when	 compared	with	 control	 group.	 Also	 in	 S+HFD	 group,	
expression	 level	 of	TRAF‐6	mRNA	was	higher	 than	 other	 groups	 (P<0.001).	 IRAK‐1	 expression	 level	
was	high	 in	S+HFD	compared	with	control	group.IL‐1β	and	TRAF‐6	mRNA	correlated	positively	with	
obesity	indexes.		
Conclusion:	The	results	showed	that	DIO	causes	overexpression	of	IL‐1β,	IRAK‐1	and	TRAF‐6	mRNA	in	
an	 experimental	 model	 of	 asthma.	 Our	 results	 suggested	 that	 in	 obese‐asthmatic	 conditions	 locally	
production	 and	 activation	 of	 pro‐inflammatory	 agents	 can	 be	 increased.	These	 findings	 showed	 that	
possible	mechanism	for	obesity‐asthma	relationships.		
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Introduction	
Epidemiological	 studies	 indicate	 an	 association	
between	obesity	 and	 asthma	 (1).	 Importantly,	most	
people	 with	 asthma	 disease	 in	 the	 emergency	
department	 of	 health	 centers	 are	 overweight	 or	
obese	 subjects	 (2).	 Clinical	 studies	have	shown	 that	
asthma	tends	to	be	very	severe	in	the	obese,	and	they	
do	 not	 respond	 fully	 to	 treatment	 with	 standard	
drugs	 (3).	 The	 airway	 hyper‐responsiveness,	 a	
characteristic	 of	 asthma,	 has	 been	 shown	 in	 obese	
mice,	 regardless	of	 the	cause	of	 their	obesity	 (4).	 In	
both	 obese	 humans	 and	 mice,	 chronic	 low‐grade	
systemic	 inflammation	 is	 characterized	 by	 an	
increase	 in	 circulating	 leukocytes	 and	 raised	 serum	
concentrations	 of	 cytokines,	 chemokine,	 and	 acute	
phase	 proteins	 (5).	 The	 effect	 of	 obesity	 on	 lung	
tissue	 involve	 in	 the	 inflammatory	 changes	 in	
pulmonary	 microenvironment	 (6).	 Therefore,	 it	 is	
important	 to	 understand	 the	 lung	 inflammation	
differences	between	obese	and	lean	subjects.	
Inflammatory	 mediators	 produced	 by	 adipose	
tissue	 may	 participate	 in	 the	 immune	 response	 of	
pulmonary	 system	 (7).	 Nevertheless,	 the	 exact	
mechanism	 of	 asthma‐obesity	 relationship	 remains	
uncertain.	 On	 the	 other	 hand,	 strong	 evidence	 in	
recent	years	had	emphasis	on	the	role	of	a	variety	of	
cytokines	in	pulmonary	inflammation	responses	(8).	
Accordingly,	studies	have	reported	that	serum	levels	
of	cytokines	in	the	blood	and	bronchoalveolar	lavage	
(BAL)	 fluid	 from	 asthmatic	 obese	 people	 have	
increased	(9).	Apart	from	the	potential	effects	of	pro‐
inflammatory	 products,	 the	 specific	 cytokines,	
particularly	 IL	 (interleukin)‐1β,	 may	 also	 interact	
with	 altered	 airway	 responsiveness	 in	 asthma.	 IL‐
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1β	 is	 a	 key	 cytokine	 involved	 in	 systemic	 and	 local	
immune	 responses	 in	 obesity	 and	 asthma.	 IL‐1β	 is	
primarily	produced	by	monocytes	and	macrophages,	
but	 other	 cells	 including	 epithelial	 cells,	 endothelial	
cells,	B	and	T	lymphocytes,	have	also	been	shown	to	
release	 IL‐1β	 (10,	 11).	 Studies	 have	 shown	 that	
treatment	 of	 animals	 with	 IL‐1	 receptor	 antagonist	
(IL‐1ra)	 could	 decrease	 hyper‐responsiveness	 to	
histamine	(12)	and	substance	P,	and	also	reduce	lung	
inflammation	and	prevent	leukocyte	infiltration	(13).	
While	many	studies	have	emphasized	the	role	of	
IL‐1β	 in	 inflammatory	 condition,	 there	 was	 little	
attention	 given	 to	 the	 autocrine	 role	 of	 IL‐1β	 in	
obesity	 associated	 with	 asthma.	 It	 has	 been	 shown	
that	 there	 is	 the	 synthesis	 of	 non‐regulated	 and	
prolonged	 release	 of	 IL‐1β	 that	 might	 involve	 with	
the	pathogenesis	of	chronic	inflammatory	conditions,	
such	 as	 inflammatory	 bowel	 disease,	 psoriasis	 and	
rheumatoid	 arthritis	 (14).	 In	 addition,	 a	 lot	 of	
evidence	is	available	that	show	that	IL‐1β	modulates	
contraction	 and	 relaxation	 responses	 in	 asthmatic	
statue	 by	 direct	 effect	 on	 airways	 (15).	 In	 signaling	
pathway,	IL‐1β	forms	a	ligand‐induced	complex	with	
IL‐1	 type	 I	 receptor	 (IL‐1RI)	 and	 IL‐1	 receptor	
accessory	 protein	 (IL‐1RAcP).	 Then,	 IL‐1	 receptor	
associated	 kinase	 (IRAK)‐1	 attaches	 to	 receptor	
complex.	 Finally,	 with	 activation	 of	 IRAK‐1,	 it	
interacts	 with	 tumor	 necrosis	 factor	 receptor	
associated	factor	(TRAF)‐6	which	is	required	for	the	
activation	 of	 IL‐1‐induced	 NF‐κB	 (16).	 This	 study	
was	proposed	 to	determine	 the	expression	of	 IL‐1β,	
IRAK‐1	 and	 TRAF‐6	 mRNA	 in	 tracheal	 tissue	 and	
evaluate	 the	 differences	 of	 their	 mRNA	 levels	 in	
obese	 and	 lean	 male	 Wistar	 rats	 in	 experimental	
asthmatic	model.	
	
Materials	and	Methods	
Animals	and	diets	
Twenty	 male	 Wistar	 rats	 (8	 weeks	 old,	 weighing	
approximately	 160	 g)	 were	 obtained	 from	 animal	
house	 of	 Tabriz	 University	 of	 Medical	 Science.	 All	
animals	 were	 placed	 in	 cages	 under	 controlled	
conditions	with	a	22	C	with	12‐12	hr	light‐dark	cycle.	
Food	 and	 water	 throughout	 the	 accommodation	 and	
experimental	period	was	provided	ad	libitum.	
After	a	week	of	accommodation,	all	rats	randomly	
divided	 to	 four	 groups	 (5	 rats	 in	 each	 group),	
included:	 control	 group	 with	 normal	 diet	 (C+ND),	
OVA‐sensitized	 group	 with	 normal	 diet	 (S+ND),	
control	group	with	high‐fat	diet	 (C+HFD),	 and	OVA‐
sensitized	 with	 high‐fat	 diet	 (S+HFD).	 Diet‐induced	
obesity	 (DIO)	model	was	prepared	according	 to	 the	
method	 to	 the	 previous	 study	 (17).	 Briefly,	 in	 DIO	
groups	(C+HFD	and	S+HFD),	rats	were	fed	with	high	
fat	 diets	 (42	%	 energy	 from	 fat,	 19%	 energy	 from	
protein	 and	 39%	 energy	 from	 carbohydrate)	 and	
other	 rats	 (C+ND	 and	 S+ND)	were	 fed	 standard	 rat	
chow	 (11%	 energy	 from	 fat,	 28%	 energy	 from	
protein	and	61%	energy	from	carbohydrate).	
After	 8	 weeks,	 sensitization	 of	 animals	 to	
ovalbumin	 (OVA)	 in	 S+ND	 and	 S+HFD	 groups	 was	
performed	with	 following	protocol.	 The	 experiment	
continued	 for	 four	 weeks	 for	 sensitized	 with	 OVA	
with	the	previous	regime.		
	
Animal	sensitization		
Sensitization	 of	 animals	 to	 OVA	 in	 S+ND	 and	
S+HFD	 groups	 was	 performed	 using	 the	 method	
described	previously	(18,	19)	 .	Briefly,	1	mg	OA	and	
200	 mg	 Al	 (OH)3	 (Sigma)	 injected	 intraperitoneal	
(IP)	on	day	1	and	8.	From	day	14,	the	animals	were	
placed	 in	 a	 closed	 chamber,	 with	 	 dimensions	
30×20×20	cm,	for	exposing	to	an	aerosol	of	4%	OVA	
for	18	±	1	days	for	15	min	daily	by	using	a	nebulizer	
(CX3,	 Omron	 Health	 care	 Europe	 B.V.,	 and	 the	
Netherlands).	All	control	animals	(C+ND	and	C+HFD)	
were	treated	similarly	but	saline	was	used	instead	of	
OVA	solution.	The	study	was	approved	by	the	Ethical	
Committee	of	Tabriz	University	of	Medical	Sciences.		
	
Body	weight	
The	 animals	were	weighted	weekly	 on	 a	 certain	
day	 (at	16.00)	during	 the	experiment.	At	 the	end	of	
study,	rats	were	anesthetized	by	50	mg/kg	ketamine	
and	xylazine	injection.	Then	they	were	weighted	and	
naso‐anal	 length;	 the	 distance	 between	 nose	 and	
anus	of	rats,	measured.	Final	body	weight,	Lee	index,	
and	 percentage	 of	 body	 fat	 (BF	 %)	 were	 also	
determined	to	calculation	of	obesity	indexes	used	in	
rodents.	 All	 obesity	 indexes	 described	 previously.	
Briefly,	 Table	 1	 shows	 how	 to	 calculate	 all	 obesity	
indexes.	
	
Biochemical	measurements	
The	 fasted	rats	after	anesthetized	with	ketamine	
and	 xylazine,	 blood	 samples	 (3‐5	 ml	 per	 rat)	 were	
collected	from	the	heart.	The	plasma	total	cholesterol	
(TC),	 triglycerides	 (TG)	 and	 HDL‐C	 concentrations	
were	measured	using	an	auto	blood	analyzer	(Bayer	
corp.	USA).	Triglycerides,	total	cholesterol	and	HDL‐
C	 kits	 were	 obtained	 from	 Pars	 Azmoon	 CO,	 Iran.	
LDL‐C	was	evaluated	using	 the	Friedewald	 formula:	
LDL‐C=	TC‐[HDL‐C+TG/5]	(20).	
	
Lysate	preparation	from	tracheal	tissue	
After	anesthetized	with	ketamine	injection,	chest	
and	neck	were	opened	and	the	trachea	was	isolated.	
Trachea	 isolated	 immediately	 weighed	 and	
recommended	 amount	 of	 tissue	 removed.	 Tissue	
grinded	 homogenized	 tissue	 was	 provided.	 Then,	
after	 adding	 of	 600	 μl	 RNase‐free	 water	 and	 20	 μl	
reconstituted	proteinase	K,	lysate	was	incubated	and	
spin	 1	 min.	 For	 the	 RNA	 binding	 to	 column,	 about	
650	 μl	 of	 lysate	 with	 ethanol	 mixture	 was	 load																				
to	column	and	centrifuged	for	1	min.	Then,	DNase	I		
	
Aslani et al                                Tracheal IL-1β pathway in obese-asthmatic rats  
    Iran J Basic Med Sci, Vol. 19, No. 4, Apr 2016 
 
352 
Table	1.	Obesity	indexes	formula	
 
Obesity	index	 Formula Reference	
Percentage	of	body	weight	changes	(%) [(Final	weight‐initial	weight)	:initial	weight]	×100	 (21)	
Lee	index	(mg/mm)	 Final	weight0.33	:	naso‐anal	length (22)	
Percentage	of	body	fat	(%)	 0.73	(lee	index‐280.8) (22)	
	
treat	performed	followed	wash	step.	RNA	was	eluted	
from	 column	 and	 the	 purified	 RNA	 sample	 kept	 at	
−70	°C	for	RT‐PCR	analysis.		
	
Real‐time	PCR	
RNA	 content	 and	 purity	 was	 measured	 using	
Nanodrop	1000	spectrophotometer	(Thermo	scientific,	
Wilmington,	 DE,	 USA).	 For	 determination	 of	 IL‐1β,	
IRAK‐1	and	TRAF‐6	mRNA	expression	levels	RevertAid	
First‐Strand	 cDNA	 Synthesis	 Kit	 (Ferment	 as	 GmBH,	
Leon‐Rot,	 Germany)	 with	 aid	 of	 random	 hexamer	
primers	 and	 MMLV	 reverse	 transcriptase	 (as	 a	
complete	 system	 for	 efficient	 synthesis	 of	 first‐strand	
cDNA	from	mRNA	or	total	RNA	templates)	were	used.	
By	 using	 SYBR	 Green	 master	 mix	 (Exiqon)	 each	
cDNA	was	 used	 as	 a	 template	 for	 separate	 assay	 for	
mRNA	 quantitative	 real‐time	 PCR.	 Table	 2	 shows	
locked	nucleic	acid	(LNA)	forward	and	reverse	primer	
sets	(Exiqon)	for	mRNA.	Real‐time	PCR	reactions	were	
performed	on	a	Rotor‐Gene	6000	instrument	(Corbett	
Life	Science,	Australia).	
The	amount	of	PCR	products	was	normalized	with	
housekeeping	 beta‐glucuronidase	 gene	 for	 mRNA	
samples	 (23).	 The	 2‐(ΔΔ	 Ct)	 method	 was	 used	 to	
determine	relative	quantitative	levels	of	IL‐1β,	IRAK‐1	
and	TRAF‐6	mRNA.	The	results	were	expressed	as	fold	
change	versus	the	relevant	controls	(24).	
	
Statistical	analysis	
Results	 were	 given	 are	 mean	 ±SD.	 The	 data	
between	different	groups	were	compared	using	one	
way	 analysis	 of	 variance	 (ANOVA)	 with	 Tukey‐
Kramer	 post‐test.	 P	 less	 than	 0.05	 were	 considered	
significant.	 The	 correlation	 between	 IL‐1β,	 IRAK‐1	
and	TRAF‐6	mRNA	 levels	with	weight	was	assessed	
with	Pearson’s	correlation	coefficient.	
	
Results	
Body	weight	
Mean	(±SD)	 initial	body	weight,	 final	body	weight,	
Lee	index,	and	percentage	of	body	fat	for	all	groups	are	
given	in	Table	3.	Results	showed	that	final	body	weight,		
	
Lee	 index,	 and	 percentage	 of	 body	 fat	 in	 C+HFD	 and	
S+HFD	 animals	 were	 significantly	 higher	 than	 C+ND	
and	S+ND	animals	(P<0.05	to	P<0.001).	But,	there	were	
no	 significant	 differences	 in	 final	 body	 weight,	 Lee	
index,	 and	 percentage	 of	 body	 fat	 between	 the	 C+ND	
versus	S+ND	and	C+HFD	versus	S+HFD.		
	
Serum	lipid	profile	
As	seen	in	Figure	1,	lipid	profile	(TC,	TG,	HDL‐C	and	
LDL‐C)	 in	 obese	 groups	 (C+HFD	 and	 S+HFD)	 were	
significantly	 higher	 than	 the	 control	 groups	 (P<0.05												
to	P<0.001).	With	the	exception	of	differences	on	HDL	
between	 C+ND	 with	 S+ND	 (P<0.05),	 a	 significant	
differences	 between	 the	 control	 groups	 together	
(C+ND	 versus	 S+ND)	 and	 obese	 groups	 together	
(C+HFD	versus	S+HFD)	were	not	observed.		
	
Relationship	 between	 lipid	 profile	 with	 IL‐1β,	
IRAK‐1,	and	TRAF‐6	mRNA	expression	
Pearson	correlation	analysis	of	 lipid	profile	with	
IL‐1	β,	IRAK‐1	and	TRAF‐6	was	shown	in	Table	4.	As	
	
	
Cholesterol
Li
pi
d 
pr
of
ile
s 
(m
g/
dl
)
0
20
40
60
80
C+ND
S+ND
C+HFD
S+HFD
Triglyceride HDL LDL
***
*** +++
+++
***
++
+++** ***
***
*
+++
+++
*
		
Figure	1.	The	serum	levels	of	total	cholesterol	(TC),	triglyceride	(TG),	
high	density	lipoprotein	(HDL‐C)	and	low	density	lipoprotein	(LDL‐C)	
in	 experimental	 groups.	 Values	 are	 depicted	 as	 mean±SD.	 C+ND;	
control	 with	 normal	 diet,	 S+ND;	 OVA‐sensitized	 with	 normal	 diet,	
C+HFD;	control	with	high‐fat	diet,	S+HFD;	OVA‐sensitized	with	high‐
fat	diet.	Statistical	differences	between	the	control	and	other	groups;	*;	
P<0.05,	 **;	 P<0.01,	 ***;	 P<0.001.	 Statistical	 differences	 between	 the	
sensitized	normal	diet	with	obese	groups;	+;	P<0.05,	++;	P<0.01,	+++;	
P<0.001.	For	each	group,	n=5	
	
		
Table	2.	Primer	set	list	for	mRNAs	
 
Gene	name	 Accession	number	 Primer	sequence	a
IL‐1β	 NM_031512	 Forward	primer		5'‐ AGA	GTG	TGG	ATC	CCA	AAC	AA	‐3'	
Reverse	primer			5'‐	AGT	CAA	CTA	TGT	CCC	GAC	CA	‐3'	
TRAF‐6	 NM_001107754.2	 Sense:																	5'‐CAG	TCC	CCT	GCA	CATT‐3'	
Antisense												3'‐GAG	GAG	GCA	TCG	CAT‐5'	
IRAK‐1	 NM_001127555	 Forward	primer			5'‐ GAG	AGT	GTT	CCT	GGC	CTC	TC	‐3'	
Reverse	primer				5'‐	GCT	GGG	TTG	ATG	ATG	ATC	TG	‐3'	
Beta	Gusp	 NM_017015	 Forward	primer					5'‐GTGGGGATAATGACTTGCAG	‐3'	
Reverse	primer						5'‐	GGAACCCCTGGTAGAACAGT‐3'	
	a.	Sequences	were	derived	from	NCBI	(www.ncbi.nlm.nih.gov)	
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Table	3.	Weight	changes	and	obesity	indexes	in	experimental	groups	
	
variables	 C+ND S+ND C+HFD S+HFD
Initial	body	weight	(g)	 158±6.67 153.20±11.38 155.20±5.40 152±10.78
Final	body	weight	(g)	 318.20±23.49 314.80±23.63 353.20±12.67 367±36.34*	+
Percentage	 of	 body	 weight	 change	
(%)	
101.18±6.34 105.96±7.73 127.81±11.89**
+
140.40±16.10***
++	
Lee	index	(mg/mm)	 304.56±7.62 306.24±3.54 319.93±2.79***
++
321.33±3.15***
++	
Percentage	of	body	fat	(%)	 19.89±5.45 18.57±2.58 28.55±2.03**
++
29.58±2.30**
++	
	Values	are	represent	as	mean±SD.	C+ND;	control	with	normal	diet,	S+ND;	OVA‐sensitized	with	normal	diet,	C+HFD;	control	with	high‐fat	
diet,	S+HFD;	OVA‐sensitized	with	high‐fat	diet.	Differences	between	the	results	of	C+ND	with	those	of	other	groups;	*;	P<0.05,	**;	P<0.01,	
***;	P<0.001.	Differences	between	the	results	of	S+ND	with	those	of	control	high	fat	diet	and	sensitized	high	fat	diet;	+;	P<0.05,	++;	P<0.01,	
+++;	P<0.001.	For	each	group,	n=5	
 
Table	4.	Pearson	correlation	analysis	of	lipid	profile	with	IL‐1	β,	IRAK‐1	and	TRAF‐6	
	
Lipid	profile	 IL‐1	β	 IRAK‐1 TRAF‐6	
r	 P‐value r P‐value r	 P‐value
Cholesterol	 0.365	 0.114 0.332 0.152 0.448	 0.048
Triglyceride	 0.438	 0.054 0.309 0.186 0.540	 0.014
HDL	 0.460	 0.041 0.409 0.073 0.482	 0.031
LDL	 0.032	 0.893 0.081 0.734 0.178	 0.452
 
 
shown,	 IL‐1	 β	 mRNA	 with	 TG	 and	 HDL	 (P<0.05),	
IRAK‐1	borderline	with	HDL	(P=0.073),	and	TRAF‐6	
with	cholesterol,	TG,	and	HDL	(P<0.05),	a	significant	
positive	correlation	was	found.	
	
IL‐1β	mRNA	expression	in	tracheal	tissue	
Figure	 2	 presents	 the	 IL‐1β	mRNA	 expressions	 in	
rat	 tracheal	 tissue.	 OVA‐sensitization	 caused	 a	
significant	 increased	 in	 IL‐1β	 mRNA	 expression	 in	
S+HFD	group	(P<0.01)	and	S+ND	group	(P<0.05)	when	
compared	 with	 C+ND	 group,	 but	 with	 C+HFD	 group	
was	 not	 significant.	 Although	 the	 amount	 of	 IL‐1β	
mRNA	 was	 higher	 in	 S+HFD	 (2.17±0.44)	 group	 than	
S+ND	(1.84±0.37)	group,	but	not	significant	differences	
were	found	between	those	groups.	There	was	not	any	
significant	 difference	 between	 C+ND	 and	 C+HFD	
groups.	
	
Relationship	between	IL‐1β	mRNA	expression	and	
obesity	indexes	
A	 significant	 positive	 correlation	 was	 found	
between	 IL‐1β	mRNA	expression	 and	percentage	 of	
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Figure	2.	Expression	level	of	IL‐1β	mRNA	in	the	tracheal	tissue	of	
experimental	 groups.	 Values	 are	 depicted	 as	 mean±SD.	 C+ND;	
control	with	normal	diet,	S+ND;	OVA‐sensitized	with	normal	diet,	
C+HFD;	 control	 with	 high‐fat	 diet,	 S+HFD;	 OVA‐sensitized	 with	
high‐fat	diet.	Statistical	differences	between	the	control	and	other	
groups;	*;	P<0.05,	**;	P<0.01.	For	each	group,	n=5	
weight	 changes	 (r=0.607,	 P<0.005;	 Figure	 3).	 This	
correlation	 was	 not	 significant	 with	 other	 obesity	
indexes,	Lee	 index	 (r=0.428,	P=0.060)	and	percentage	
of	body	fat	(r=0.344,	P=0.138).	
	
IRAK‐1	mRNA	expression	in	tracheal	tissue	
In	Figure	4,	IRAK‐1	mRNA	expressions	in	tracheal	
tissue	 in	 different	 groups	 are	 shown.	 The	 IRAK‐1	
mRNA	 expressions	 in	 group	 S+HFD	 increased	
significantly	compared	to	C+ND	(P<0.01)	and	C+HFD	
(P<0.05)	 groups,	 but	 was	 not	 seen	 any	 significant	
difference	 with	 S+ND	 group.	 Also,	 IRAK‐1	 mRNA	
expression	in	normal	diet	sensitized	group	increased	
significantly	 compared	with	 C+ND	 (P<0.05),	 but	 no	
difference	greater	 than	C+HFD	group	was	observed.	
There	 was	 not	 any	 significant	 difference	 between	
C+ND	with	C+HFD.			
	
Relationship	 between	 IRAK‐1	 mRNA	 expression	
and	obesity	indexes	
There	 was	 not	 significant	 correlation	 between	
IRAK‐1	mRNA	expression	with	obesity	indexes,	
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Figure	 3.	 Pearson	 correlation	 analysis	 of	 IL‐1β	 mRNA	 with	
percentage	of	body	weight	changes	in	the	study	groups.	There	was	
a	 significant	 positive	 correlation	 between	 IL‐1	mRNA	 expression	
and	 percentage	 of	 body	 weight	 changes	 (correlation	 coefficient	
=0.434,	P<0.05)	
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Figure	4.	Expression	 level	of	 IRAK‐1	mRNA	in	the	 tracheal	tissue	of	
experimental	groups.Values	are	depicted	as	mean±SD.	C+ND;	control	
with	 normal	 diet,	 S+ND;	 OVA‐sensitized	 with	 normal	 diet,	 C+HFD;	
control	with	high‐fat	 diet,	 S+HFD;	OVA‐sensitized	with	high‐fat	 diet,	
TRAF‐6;	 TNF	 receptor	 associated	 factor‐6.	 Differences	 between	 the	
results	of	normal	diet	with	those	of	other	groups;	*;	P<0.05,	**;	P<0.01.	
Differences	between	the	results	of	control	high	fat	diet	with	those	of	
sensitized	high	fat	diet;	#;	P<0.05.	For	each	group,	n=5	
			
percentage	of	weight	 changes	 (r=0.398,	P<0.082),	Lee	
index	 (r=0.178,	 P=0.453)	 and	 percentage	 of	 body	 fat	
(r=0.090,	P=0.707).		
	
TRAF‐6	mRNA	expression	in	tracheal	tissue	
Figure	5	shows	that	TRAF‐6	mRNA	expressions	in	
group	 S+HFD	 increased	 significantly	 compared	 to	
C+ND,	 C+HFD,	 and	 S+ND	groups	 (P<0.001).	 Despite	
high	 TRAF‐6	 mRNA	 expression	 in	 lean	 sensitized	
group	(1.49±0.50),	this	increase	was	not	statistically	
significant	 compared	 with	 lean	 and	 obese	 non‐
sensitized	 groups.	 There	 was	 not	 any	 significant	
difference	between	C+ND	with	C+HFD.	
	
Relationship	 between	 TRAF‐6	 mRNA	 expression	
and	obesity	indexes	
There	was	a	positive	correlation	between	TRAF‐6	
mRNA	expression	and	percentage	of	weight	changes	
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Figure	5.	Expression	level	of	TRAF‐6	mRNA	in	the	tracheal	tissue	
of	 experimental	 groups.Values	 are	 depicted	 as	 mean±SD.	 C+ND;	
control	with	normal	diet,	S+ND;	OVA‐sensitized	with	normal	diet,	
C+HFD;	 control	 with	 high‐fat	 diet,	 S+HFD;	 OVA‐sensitized																			
with	 high‐fat	 diet,	 TRAF‐6;	 TNF	 receptor	 associated	 factor‐6.	
Differences	between	the	results	of	normal	diet	with	those	of	other	
groups;	***;	P<0.001.	Differences	between	the	results	of	sensitized	
normal	diet	with	those	of	control	high	fat	diet	and	sensitized	high	
fat	diet;	 +++;	P<0.001.	Differences	between	 the	 results	 of	 control	
high	 fat	diet	with	 those	of	 sensitized	high	 fat	diet;	###;	P<0.001.	
For	each	group,	n=5	
(r=	 0.704,	 P<0.001;	 Figure	 6).	 But	 this	 correlation	
was	 not	 significant	when	 compared	with	 Lee	 index																					
(r=	 0.443,	 P=0.050)	 and	 percentage	 of	 body	 fat																			
(r=	0.413,	P=0.71).		
	
Discussion	
In	the	present	study	the	effect	of	high	fat	diet	on	
IL‐1	 β,	 IRAK‐1	 and	 TRAF‐6	 mRNA	 expression	 in	
trachea	 of	 OVA‐sensitized	 and	 non‐sensitized	 male	
Wistar	rats	were	examined.	
The	present	study	indicated	that	enhanced	IL‐1	β	
mRNA	 expression	 in	 trachea	 in	 sensitized	 lean	 and	
obese	rats	compared	with	non	sensitized	obese	and	
lean	control	groups.	Although,	the	most	increase	was	
seen	 in	 obese	 sensitized	 group,	 but	 the	 difference	
was	 not	 statistically	 significant	 with	 non‐obese	
sensitized	 group.	 Although	 a	 significant	 positive	
correlation	 was	 seen	 between	 IL‐1β	 mRNA	
expression	 and	 the	 value	 of	 the	 percent	 weight	
changes,	 this	 correlation	 was	 not	 significant	 with	
other	obesity	indexes	(Lee	and	fat	percent)	in	rodent.	
After	diet‐induced	obesity	 and	 sensitized	with	OVA,	
TRAF‐6	 mRNA	 expression	 in	 trachea	 was	 highly	
significant	 in	 obese	 sensitized	 rats	 compared	 with	
other	 groups.	 The	 correlation	 of	 TRAF‐6	 mRNA	
expression	 in	 trachea	 with	 percentage	 weight	
changes	 also	 was	 positively	 significant,	 but	 there	
were	 not	 significant	 correlation	 with	 other	 obesity	
indexes.	 Moreover,	 IRAK‐1	 mRNA	 expression	 was	
high	 in	 obese	 sensitized	 rats	 when	 compared	 with	
control	and	obese	non	sensitized	groups.	There	was	
not	 correlation	 between	 IRAK‐1	mRNA	 and	 obesity	
indexes	in	rodent.			
Obesity	 in	 humans	 is	 mostly	 derived	 from																		
the	 interaction	 of	 consumption	 high	 fat	 diet	 and															
low	expenditure	of	energy	(25).	The	high	prevalence	
of	 asthma	 in	 overweight	 and	 obesity	 in	 adults	 and	
children	 has	 been	 shown	 by	 several	 clinical																	
trials	(26).	Different	kinds	of	genetically	engineered	
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Figure	 6.	 Pearson	 correlation	 analysis	 of	 TRAF‐6	 mRNA	 with	
percentage	of	body	weight	changes	in	the	study	groups.	There	was	
a	 significant	 positive	 correlation	 between	 IL‐1	mRNA	 expression	
and	 percentage	 of	 body	 weight	 changes	 (correlation	 coefficient	
=0.686,	P<0.001)	
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animals	 were	 used	 to	 investigate	 the	 mechanisms	
responsible	 to	 this	 possible	 relationship	 between	
obesity	and	asthma.	The	genetically	obese	mice	have	
some	complications	by	comorbid	conditions	 in	their	
studies	 designs	 such	 as	 leptin	 deficiency	 (ob/ob	
mouse)	 and	 leptin	 receptor	 deficiency	 (db/db	
mouse)	 which	 may	 affect	 on	 defective	 innate	 and	
adaptive	immune	responses	in	airways	(27).	So,	 the	
model	of	obesity	caused	by	high	fat	diet	was	used	in	
this	 study.	 Wistar	 rats	 showed	 increased	 body	
weight	 and	 obesity	 index	 (percentage	 of	 weight	
changes,	Lee	index	and	fat	percent)	after	eating	high	
fat	 diet	 for	 12	 weeks	which	 were	 seen	 in	 previous	
studies	 using	 the	 same	 method	 of	 diet‐induced	
obesity	 (17).	 In	 addition,	 analysis	 of	 lipid	 profiles	
(cholesterol,	 triglyceride,	 HDL‐C	 and	 LDL‐C)	 in	 this	
study	 showed	 that	 diet‐induced	 obesity	 caused	 a	
significant	increased	in	lipid	profiles.	
Obesity	 is	a	 low‐grade	chronic	pro‐inflammatory	
state	that	affects	immune	system	responses	of	obese	
asthmatic	 individuals,	 causes	 inflammation	 of	
airways	 and	 consequently	 can	 be	 lead	 to	
deterioration	 of	 asthma	 (28).	 It	 seems	 that	 the	
measurement	 of	 the	 effects	 of	 inflammation	 in	 the	
airways	shows	a	better	understanding	of	the	role	of	
inflammation	 in	 obese	 asthmatic	 patients	 than	 its	
measurement	 systemically.	 Local	 inflammation	 in	
arthrosclerosis	 plaque	 has	 the	 main	 role	 in	 the	
pathogenesis	 of	 coronary	 arterial	 disease	 and	
systemic	 inflammation	 is	 thought	 to	 interact	 with	
this	 process	 (29).	 Perhaps	 such	 a	 similar	 theory	 is	
also	associated	in	the	obese	asthmatic	conditions.	
There	is	strong	evidence	in	recent	years	that	have	
emphasized	 on	 a	 variety	 of	 cytokines	 in	 pulmonary	
inflammatory	 response	 in	 developing	 asthma	 (30).	
Specific	 cytokines,	 particularly	 IL‐1β,	 may	 have	 an	
interaction	with	the	change	of	airway	responsiveness	
in	 asthma	 (14).	 It	 has	 been	 demonstrated	 that																
IL‐1β	 caused	 airway	 hyper‐responsiveness	 and	
impairment	 of	 beta	 adrenergic	 relaxation	 in	
experimentally	 induced	 asthma	 model	 (31).	
Accordingly,	studies	have	shown	that	treatment	with	
IL‐1	antagonist	prevented	the	hyper‐responsiveness	
and	 decreased	 relaxation	 response	 in	 sensitized	
airways	 (32).	 In	 addition,	 the	 new	 evidence	 shows	
IL‐1β‐inducing	 expression	 by	 its	 airway	 smooth	
muscle	(ASM),	and	strongly	implying	to	function	and	
releasing	 autocrine	 IL‐1β	 by	 ASM	 in	 autologous	
manner	(33).		
In	 this	 study,	 the	 increased	 expression	 of	 IL‐1β	
mRNA	in	 trachea	was	seen	 in	experimental	 induced	
asthma,	which	was	consistent	with	previous	findings	
(34).	Interestingly,	the	diet‐induced	obesity	in	obese	
sensitized	 group	 enhanced	 the	 IL‐1β	 mRNA	
expression	 in	 trachea	 that	 was	 the	 same	 with	 the	
findings	of	Lu	et	al	in	lung	tissue	(35).	Indeed,	it	has	
found	 that	 the	 expression	 of	 IL‐1β	 mRNA	 in	 obese	
asthmatic	group	was	associated	with	the	elaborating	
IL‐1β	 into	 the	 trachea	 tissue.	 These	 findings	
indicated	that	diet‐induced	obesity	in	sensitized	rats	
could	 induce	autologous	expression	of	 IL‐1β	mRNA,	
and	this	made	an	autocrine	effects	on	airway	cell	that	
was	 along	 with	 the	 release	 of	 extracellular	 IL‐1β	
protein.	 Subsequently,	 IL‐1β	 would	 increase	 the	
synthesis	and	release	of	other	mediators	which	could	
lead	 to	 exacerbation	 of	 lung	 inflammation	 (13).	
Although	 the	 direct	 effects	 of	 IL‐1β	 were	 not	
determined	 in	 the	 current	 study,	 the	 autocrine	
mechanisms	may	be	 involved	 in	pathophysiology	of	
obesity	 associated	 with	 asthma.	 The	 relative	
interaction	 of	 gene	 transcription	 of	 IL‐1β	 versus	
regulation	 of	 post	 translation	 of	 IL‐1β	 mRNA	
expression	has	not	revealed	yet.	
In	 an	 effort	 to	 further	 understanding	 of	 the	 IL‐
1β's	 role	 in	 relationship	 between	 obesity	 and	
asthma,	the	IRAK‐1	and	TRAF‐6	mRNA	expression	in	
trachea	 was	 tested	 in	 study	 groups.	 IL‐1	 signal	
transduction	 pathways	 are	 interaction	 with	 TNF	
receptor	 associated	 (TRAF)	 adaptor	 proteins,	
especially	 TRAF‐6.	 TRAF‐6	 interacts	 with	 IL‐1	
receptor	associated	kinase	(IRAK)	which	is	recruited	
to	and	activated	by	the	IL‐1	receptor	complex	(36).	
Our	 results	 showed	 that	 diet‐induced	 obesity	
caused	overexpression	of	IRAK‐1	and	TRAF‐6	mRNA	
in	 obese	 sensitized	 group.	 The	 expression	 levels	 of	
IRAK‐1	 mRNA	 in	 OVA‐sensitized	 groups,	 lead	 to	
increased	 expression.	 On	 the	 other	 hand,	 although	
the	 TRAF‐6	 mRNA	 expression	 was	 high	 in	 lean	
sensitized	 group,	 however,	 there	 was	 not	 any	
statistically	significance	with	non‐sensitized	lean	and	
obese	 groups.	 	 Obvious	 studies	 have	 been	 shown	
increased	 IRAK‐1	 and	 TRAF‐6	mRNA	 expression	 in	
animal	 allergic	 and	 sensitized	 asthma	model	 which	
similar	to	current	study.	Our	results	also	showed	that	
the	 expression	 of	 IRAK‐1	 and	 TRAF‐6	 mRNA	 more	
increased	 in	 obesity	 associated	 with	 asthma.	 IL‐1β	
promotes	 most	 its	 function	 by	 the	 activation	 of	
transcription	of	gene	coding	of	chemokine,	cytokines,	
acute‐phase	 proteins,	 and	 adhesion	molecules.	 As	 a	
result	 expose	 cell	 with	 cytokines	 and	 other	
extracellular	 stimuli,	 IL‐1β	 associates	 with	 its	
receptors	and	recruitment	of	IRAK1‐TRAF6	signaling	
pathways	to	exert	of	activation	transcription	factors,	
particularly	 NF‐κB.	 Overexpression	 of	 IRAK‐1	 and	
TRAF‐6	mRNA	 in	obese	 sensitized	group,	at	 least	 in	
part,	might	explain	 the	possible	role	of	 IL‐1β	 in	 this	
condition,	however,	the	role	of	other	factors	such	as	
role	of	Toll‐like	receptors	and	free	fatty	acids,	cannot	
be	 ruled	 out	 in	 IRAK‐1/TRAF‐6	 activation	 (37).	
Increased	 the	 expression	 of	 IRAK‐1	 and	 TRAF‐6	
mRNA,	and	on	the	other	hand,	 increased	expression	
of	 IL‐1β	 mRNA	 in	 trachea	 in	 obese	 sensitized	
condition,	maybe	indicate	their	interaction.		
It	 should	 be	 noted	 that	 the	 complexity	 of	 the	
mechanisms	 responsible	 for	 exert	 IL‐1β	 autocrine	
effects	 is	difficult	 to	explain	 in	obesity	with	asthma.	
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In	 fact,	 other	 members	 of	 IL‐1	 axis	 should	 be	
considered	for	better	understanding	of	the	role	of	IL‐
1β.	 Studies	 have	 shown	 that	 IL‐1	 exerts	 its	 effects	
through	the	IL‐1	type	I	receptor	(IL‐1RI),	but	type	2	
receptors;	 both	 IL‐1RII	 and	 solution	 form	of	 it	 (sIL‐
1RII)	 and	 solution	 form	 of	 IL‐1RI	 (sIL‐1RI),	 act	 as	
decoy	receptors	 that	are	 involved	as	damping	effect	
for	 IL‐1	 (38).	 Also,	 IL‐1ra,	 an	 endogen	 IL‐1	
antagonist,	 should	be	 considered	 in	 this	 axis.	Based	
on	 available	 evidence,	 it	 seems	 that	 under	 normal	
conditions,	 IL‐1β	 and	 other	 family	members	 of	 IL‐1	
are	 involved	to	prevent	excessive	 immune	response	
in	all	cell	type.	On	the	other	hand,	in	certain	disease	
conditions,	there	is	an	imbalance	in	the	production	of	
the	 IL‐1β	 and	 other	 molecules	 in	 IL‐1	 axis,	 this	
phenomenon	 might	 occur	 in	 obese	 with	 asthma.	
Although	the	expression	of	IL‐1β	mRNA	increased	in	
the	 current	 study,	 the	 role	 of	 other	 molecules	
involved	in	IL‐1axis	cannot	be	ruled	out.	Perhaps	the	
expression	or	activation	of	other	molecules	reduced	
or	 activated	 in	 obesity	 associated	with	 asthma	 that	
required	 further	 studies.	 So,	 the	 ratio	 of																
active	 (IL‐1RI)	 to	 inactive	 (sIL‐1RI,	 IL‐1RII,	 and	 sIL‐
1RII)	 receptors	 may	 determine	 the	 amount	 of	
inflammation.	
This	study	examined	the	correlation	between	the	
expression	of	IL‐1β,	IRAK‐1	and	TRAF‐6	mRNA	with	
obesity	 indexes	 in	 rodent.	 The	 result	 showed	 that	
there	 was	 a	 positive	 correlation	 between	 the	
expression	 of	 IL‐1β	 and	 TRAF‐6	 mRNA	 with	
percentage	 of	 weight	 changes	 in	 study	 groups,	
however,	this	correlation	was	weak.	As	noted	above,	
despite	 of	 exit	 positive	 correlation	 in	 different	
groups;	there	was	no	significant	correlation	between	
IL‐1β,	IRAK‐1	and	TRAF‐6	mRNA	with	Lee	index	and	
percentage	 of	 body	 fat.	 Interestingly,	 the	 analysis	
was	done	for	different	groups	separately	in	order	to	
determine	the	relationship	between	obesity	 indexes	
and	related	gene	expression	in	this	study,	despite	the	
positive	linear	correlation	in	most	groups,	there	was	
no	 significant	 difference	 (data	 not	 published).	 The	
reason	 for	 this	 lack	 of	 significance	 may	 be	 limited	
samples.	 However,	 this	 study	 showed	 that	 enhance	
in	 weight	 increases	 expression	 of	 inflammatory	
cytokines,	 IL‐1β.	 Studies	 have	 shown	 that	
conventional	 biomarkers	 in	 asthma,	 eosinophil	 and	
eNO,	 do	 not	 increase	 substantially	 with	 increasing	
body	 mass	 index	 (BMI).	 The	 study	 suggests	 that	
obesity	may	 impact	 the	 severity	 of	 asthma	 through	
the	 other	 mechanisms	 (39).	 A	 novel	 adipokine	
visfatin	 (a	 pro‐inflammatory	 factor)	 plays	 a	 role	 in	
several	 diseases	 related	 with	 inflammation	 such	 as	
asthma	(40).	However,	very	little	is	known	about	the	
role	of	visfatin	in	asthma	and	need	further	research.	
Based	 on	 the	 above	 observation,	 it	 is	 conceivable	
that,	 asthma	 phenotype	 might	 changes	 in	 obesity	
condition.	
	
Conclusion	
The	results	of	this	investigation	showed	that	diet‐
induced	 obesity	 caused	 an	 increased	 expression	 of	
IL‐1β,	IRAK‐1	and	TRAF‐6	mRNA	in	trachea	of	male	
OVA‐sensitized	 rats.	 IL‐1β	 is	 a	 cytokine	 which	 has	
pro‐inflammatory	 effects.	 Elevated	 of	 IL‐1β	 mRNA	
expression	 in	 obesity	 condition	 may	 be	 result	 in	
exacerbation	 of	 inflammation	 of	 airways	 in	 asthma.	
IL‐1β	has	local	and	systemic	effects.	Increased	of	IL‐
1β	 in	 circulating,	 with	 its	 autocrine	 effect	 may	
involve	 in	 increase	 of	 inflammation	 in	 obesity	
associated	with	asthma	 in	airways.	Also,	 IL‐1	exerts	
its	effects	 through	 the	 IRAK‐1	and	TRAF‐6	after	 the	
band	 with	 its	 receptor.	 Increased	 expressions	 of	
IRAK‐1	 and	 TRAF‐6	 mRNA	 in	 this	 study,	 to	 some	
extent,	 can	 show	 activation	 of	 IL‐1	 signaling	
pathways.	 On	 the	 other	 hand,	 increased	 expression	
of	 IL‐1β,	 at	 least	 in	 part,	 may	 explain	 decrease	 the	
response	of	trachea	to	relaxant	drugs	in	obesity	with	
asthma.	
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